Get the Stockscreener App
63.82
5.21%
-3.51
Genedx Holdings Corp stock is traded at $63.82, with a volume of 491.18K.
It is down -5.21% in the last 24 hours and down -25.15% over the past month.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
See More
Previous Close:
$67.33
Open:
$67.33
24h Volume:
491.18K
Relative Volume:
0.64
Market Cap:
$1.90B
Revenue:
$442.68M
Net Income/Loss:
$-77.81M
P/E Ratio:
-23.92
EPS:
-2.6684
Net Cash Flow:
$-28.65M
1W Performance:
-10.77%
1M Performance:
-25.15%
6M Performance:
+4.66%
1Y Performance:
-47.20%
1-Day Range:
$0.00
$0.00
1-Week Range:
$63.50
$71.43
52-Week Range:
$32.21
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Name
Genedx Holdings Corp
Sector
Industry
Phone
888-729-1206
Address
333 LUDLOW STREET, STAMFORD
Compare WGS vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
63.82 | 1.90B | 442.68M | -77.81M | -28.65M | -2.6684 |
TMO
Thermo Fisher Scientific Inc
|
662.24 | 244.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
221.20 | 155.50B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
397.77 | 57.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
171.33 | 48.30B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.21 | 43.16B | 16.63B | 1.39B | 2.12B | 8.0674 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-15-25 | Initiated | Guggenheim | Buy |
| May-09-25 | Upgrade | Jefferies | Hold → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-10-24 | Initiated | Craig Hallum | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
View All
Genedx Holdings Corp Stock (WGS) Latest News
Encompass Health Expands Rehab Footprint With New Maine Hospital - Zacks Investment Research
GeneDx Holdings (NasdaqGS:WGS) Stock Forecast & Analyst Predictions - Simply Wall Street
GeneDx CEO Katherine Stueland sells $1.03m in stock - Investing.com
GeneDx Director Thomas Fuchs Reports RSU Conversion to 1,146 Shares - Kalkine Media
GeneDx (WGS) CEO sells 10,501 shares to cover taxes - Stock Titan
Tax-driven stock sale by GeneDx (WGS) CFO after RSU vesting - Stock Titan
GeneDx Holdings (WGS) director receives 1,146 shares at no cash cost - Stock Titan
GeneDx (WGS) CEO sells shares in tax-withholding trade - Stock Titan
GeneDx (WGS) CFO sells stock for taxes, holds 41,476 shares - Stock Titan
WGS: GeneDx Holdings Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C - Yahoo Finance
GeneDx at Wells Fargo healthcare conference: growth and collections in focus - Investing.com Canada
GeneDx at Wells Fargo healthcare conference: growth and collections in focus - Investing.com UK
GeneDx Holdings CFO Kevin Feeley Executes 717 Shares at $0 and Sells at $83.84 on Sept. 1, 2026 - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out - ACCESS Newswire
GeneDx Holdings (WGS) CFO sells shares in tax-cover trade - Stock Titan
Insider at GeneDx (NASDAQ: WGS) lines up new stock sale after June tax trades - Stock Titan
Planned $1.2M insider sale at GeneDx (NASDAQ: WGS) tied to 2026 RSU vesting - Stock Titan
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm - Eastern Progress
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree - marketscreener.com
WGS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against GeneDx Holdings Corp - Eastern Progress
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics AcquisitionHBSS - Eastern Progress
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit - Eastern Progress
WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
GeneDx Holdings (WGS) Study Data Puts Its Fair Value Debate Back In Focus - Sahm
A GeneDx study found genetic diagnoses in 63% of children with faltering growth - Stock Titan
A Look at GeneDx Holdings Corp (WGS) After 5.5% Gain -- GF Value $73.66 vs Price $87.06 - GuruFocus
GeneDx Holdings Corp. $WGS Shares Purchased by Bank of America Corp DE - MarketBeat
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Cor - The National Law Review
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-08-18 | GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:WGS | Press Release - Stockhouse
GeneDx: Why I Think The Worst Is Behind The Business (NASDAQ:WGS) - Seeking Alpha
WGS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Inv - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
WGS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
GeneDx Holdings (WGS) Slips 1.35% to $78.08, Holds Midpoint of Trading RangeCall Flow Alert - Vinanet
GeneDx Holdings (WGS) Slips 1.35% as Shares Hold Between Key Support and ResistanceDelta Hedging - Vinanet
GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention? - Sahm
Precision Trading with Genedx Holdings Corp. (WGS) Risk Zones - Stock Traders Daily
The Manufacturers Life Insurance Company Sells 12,820 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect - ACCESS Newswire
Sei Investments Co. Trims Stock Position in GeneDx Holdings Corp. $WGS - MarketBeat
WGS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Va - GuruFocus
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Goldman Sachs Group (WGS) discloses 5.8% beneficial stake in GeneDx Class A - Stock Titan
GeneDx at Canaccord Genuity conference: volume rises, collections lag - Investing.com
Genedx Holdings Corp Stock (WGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genedx Holdings Corp Stock (WGS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fuchs Thomas | Director |
Sep 17 '26 |
Option Exercise |
0.00 |
1,146 |
0 |
1,146 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 16 '26 |
Sale |
97.61 |
3,728 |
363,892 |
44,945 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 16 '26 |
Option Exercise |
0.00 |
7,197 |
0 |
48,673 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Sale |
97.61 |
10,501 |
1,025,013 |
115,476 |
| Katherine Stueland | Officer |
Sep 09 '26 |
Proposed Sale |
84.82 |
14,243 |
1,208,100 |
0 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 09 '26 |
Sale |
84.22 |
1,285 |
108,220 |
41,476 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 09 '26 |
Option Exercise |
0.00 |
2,462 |
0 |
42,761 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 09 '26 |
Sale |
84.22 |
3,692 |
310,932 |
107,227 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 09 '26 |
Option Exercise |
0.00 |
6,547 |
0 |
110,919 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 01 '26 |
Option Exercise |
0.00 |
717 |
0 |
40,671 |
0.92%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):